Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Xiaflex Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.02.85

    Xiaflex (collagenase clostridium histolyticum) Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.02.85 alerts

    Get alerted when Policy 05.02.85 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization requirements for Xiaflex for adults with Dupuytren's contracture or Peyronie's disease. Coverage requires applicable clinical, documentation, provider, and dosing criteria, and benefits remain subject to the member's contract.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyXiaflex (collagenase clostridium histolyticum)
    Policy CodePolicy 05.02.85
    Change TypeNo material change
    Effective DateOct 18, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before therapy and submit the covered indication, clinical documentation, and approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered indications
    6 monthsDupuytren's authorization
    12 monthsPeyronie's authorization
    3/cordDupuytren's limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    8 total
    Peyronie's limit
    J0775HCPCS code

    Coverage Criteria

    Initial Therapy — Dupuytren's Contracture

    Authorization of 6 months may be granted for the treatment of Dupuytren's contracture when all of the following criteria are met:

    ALL of the following

    • The member has a finger flexion contracture with a palpable cord in a metacarpophalangeal joint or a proximal interphalangeal joint prior to initiating Xiaflex therapy.
    • The contracture is at least 20 degrees prior to initiating Xiaflex therapy.>= 20 degrees
    • The member had a positive tabletop test, defined as the inability to simultaneously place the affected finger(s) and palm flat against a table prior to initiating Xiaflex therapy.
    • The member is 18 years of age or older.>= 18 years
    • The member will receive up to 3 injections maximum per cord, administered 4 weeks apart, as part of the current treatment.<= 3 injections per cord; 4 weeks apart

    Initial Therapy — Peyronie's Disease

    Authorization of 12 months may be granted for the treatment of Peyronie's disease when all of the following criteria are met:

    ALL of the following

    • The member has stable Peyronie's disease without clinical changes, such as worsening curvature, for at least three months.>= 3 months stable
    • The member has a palpable plaque and curvature deformity of at least 30 degrees and less than or equal to 90 degrees prior to initiating Xiaflex therapy.30–90 degrees
    • The member has intact erectile function, with or without medication.
    • The member is 18 years of age or older.>= 18 years

    Continuation Therapy — Dupuytren's Contracture

    Authorization of 6 months may be granted for the continuation of treatment for Dupuytren's contracture when all of the following criteria are met:

    ALL of the following

    • The member meets all initial authorization criteria.
    • Treatment is continuing for one of the following:

      • The member is continuing with a treatment course for the same cord.
      • The member is being treated for a new cord or a previously treated cord following recurrence and meets all initial authorization criteria.
    • The member has received less than 3 injections total per cord, administered 4 weeks apart.< 3 injections per cord; 4 weeks apart

    Continuation Therapy — Peyronie's Disease

    Authorization of 12 months may be granted for the continuation of treatment for Peyronie's disease when all of the following criteria are met:

    ALL of the following

    • The member meets all initial authorization criteria.
    • The member has curvature deformity of at least 15 degrees at the time of the continuation request.>= 15 degrees
    • The member has received less than 8 injections total, including any injections the patient has received for any previous treatment.< 8 injections total

    Coverage will not be provided for cosmetic use, including cellulite reduction treatment.

    Xiaflex is considered not medically necessary for members who do not meet the criteria set forth above.

    Coding and Clinical Thresholds

    HCPCS CodeHCPCS
    J0775Injection, collagenase, clostridium histolyticum, 0.01 mg
    Dupuytren's Contracture Angle
    IndicationDupuytren's contracture
    Minimum contracture angleAt least 20 degrees
    TimingRequired prior to initiating Xiaflex therapy
    Peyronie's Disease Curvature at Initiation
    IndicationPeyronie's disease
    Curvature rangeAt least 30 degrees and less than or equal to 90 degrees
    TimingRequired prior to initiating Xiaflex therapy

    Provider Requirements and Action Items

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Xiaflex. Coverage may be authorized for Dupuytren's contracture for 6 months or Peyronie's disease for 12 months when all applicable approval criteria are met and the member has no exclusion; submit the indication-specific clinical documentation required for review.

    • Covered indications: Dupuytren's contracture and Peyronie's disease.
    • Include the required chart notes or medical records and, for continuation requests, the member's cumulative injection history.
    • Authorization is subject to the indication-specific clinical, age, injection-limit, and continuation criteria below.
    Documentation Required

    Clinical Documentation Required

    Submit chart notes or medical records supporting the requested indication and documenting the required baseline or continuation findings. Documentation must also identify the number of Xiaflex injections already received when requesting continuation.

    Policy Background

    Xiaflex is an injectable collagenase used for selected adults with Dupuytren's contracture or Peyronie's disease. Coverage is limited to these covered indications and requires objective disease findings, applicable age and treatment-course limits, and prior authorization. For Dupuytren's contracture, treatment addresses a finger flexion contracture associated with a palpable cord; for Peyronie's disease, treatment addresses a palpable plaque with specified penile curvature. Adults must be 18 years or older.

    Definitions

    Positive Tabletop Test
    Test findingPositive tabletop test
    Affected fingersThe affected finger(s) cannot be placed flat against a table
    Palm findingThe palm cannot be placed simultaneously flat against the table
    Stable Peyronie's Disease
    ConditionPeyronie's disease without clinical changes
    Examples of changeClinical changes include worsening curvature
    Stability periodAt least three months

    Initial Therapy Criteria

    Dupuytren's Contracture Initial Therapy

    Covered when all of the following are met:

    Dupuytren's contracture initial therapy

    • The member has a finger flexion contracture with a palpable cord in a metacarpophalangeal joint or a proximal interphalangeal joint prior to initiating Xiaflex therapy.
    • The contracture is at least 20 degrees prior to initiating Xiaflex therapy.≥20 degrees
    • The member has a positive tabletop test, defined as the inability to simultaneously place the affected finger(s) and palm flat against a table, prior to initiating Xiaflex therapy.
    • The member is 18 years of age or older.≥18 years

    Continuation Criteria

    Dupuytren's Contracture Continuation

    Covered when all of the following are met:

    Dupuytren's contracture continuation

    • The member meets all initial authorization criteria.
    • The member is continuing with a treatment course for the same cord.

      For treatment of a new cord or a previously treated cord following recurrence, the member must meet all initial authorization criteria.

    • The member has received fewer than 3 injections total per cord, with injections 4 weeks apart.<3 injections total per cord, 4 weeks apart

    Peyronie's Disease Continuation

    Covered when all of the following are met:

    Provider and Administration Requirements

    StepIndicationAdministration requirement
    1Dupuytren's contractureXiaflex must be administered by a healthcare provider experienced in injection procedures of the hand and in the treatment of Dupuytren's contracture.
    1Peyronie's diseaseXiaflex must be administered by a healthcare provider experienced in the treatment of urological disease and who has completed the Xiaflex REMS program requirements.

    Quantity and Treatment Limits

    Xiaflex for Dupuytren's Contracture
    Injection quantityUp to 3 injections maximum per cord
    Injection intervalInjections are administered 4 weeks apart
    Continuation limitContinuation requires fewer than 3 injections total per cord
    Xiaflex for Peyronie's Disease
    Treatment courseMaximum of one treatment course
    Total injectionsMaximum of 8 injections total
    Continuation limitContinuation requires fewer than 8 total injections, including previous treatment
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyXiaflex (collagenase clostridium histolyticum)
    Policy CodePolicy 05.02.85
    Change TypeNo material change
    Effective DateOct 18, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before therapy and submit the covered indication, clinical documentation, and approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Requirements and Action ItemsPolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaProvider and Administration RequirementsQuantity and Treatment Limits
  1. The member will receive a maximum of one treatment course with a maximum of 8 injections total, including any injections the patient has received for any previous treatment.1 course; <= 8 injections total
  2. Peyronie's Disease Curvature at Continuation
    IndicationPeyronie's disease continuation therapy
    Minimum curvatureAt least 15 degrees
    TimingRequired at the time of the continuation request
    Dupuytren's Injection Limit
    Maximum per cordUp to 3 injections
    IntervalInjections must be 4 weeks apart
    Continuation limitFewer than 3 injections total per cord
    Peyronie's Injection Limit
    Treatment-course limitMaximum of one treatment course
    Total injection limitMaximum of 8 injections total
    Previous treatmentThe 8-injection limit includes injections received for any previous treatment
    Minimum Age
    Minimum member age18 years or older
    Dupuytren's contractureThe age requirement applies before Xiaflex therapy
    Peyronie's diseaseThe age requirement applies before Xiaflex therapy
    • Dupuytren's contracture: Document the affected joint, contracture, and a positive tabletop test for new starts and continuation requests; provide the number of injections received for continuation.
    • Peyronie's disease: Document palpable plaque, curvature, and intact erectile function, with or without medication, for new starts and continuation requests; provide the number of injections received for continuation.
    Note

    Prescriber and Administering-Provider Qualifications

    Ensure Xiaflex is administered by a provider who meets the indication-specific experience requirements.

    • Dupuytren's contracture: The administering healthcare provider must be experienced in hand injection procedures and treatment of Dupuytren's contracture.
    • Peyronie's disease: The administering healthcare provider must be experienced in treating urological disease and must have completed the Xiaflex REMS program requirements.
    Denial Risk

    Cosmetic Use Excluded

    Xiaflex coverage is not provided for cosmetic use, including cellulite reduction treatment.

    • Do not submit Xiaflex for cosmetic treatment or cellulite reduction.
    Denial Risk

    Failure to Meet Continuation Criteria

    Xiaflex is considered not medically necessary when the member does not meet the applicable continuation criteria for the requested indication.

    • Verify that all initial criteria remain satisfied when required and that the continuation-specific clinical findings and cumulative injection limits are documented before requesting additional treatment.
    Denial Risk

    Criteria and Dose-Limit Failure Risks

    Requests may be denied when any clinical criterion, age requirement, injection limit, or continuation requirement is not met. Confirm the applicable limits before treatment and account for prior Xiaflex injections in the member's total.

    • Dupuytren's initial therapy: The member must be at least 18 years old; have a finger flexion contracture with a palpable cord in a metacarpophalangeal or proximal interphalangeal joint; have a contracture of at least 20 degrees; have a positive tabletop test; and receive no more than 3 injections per cord, 4 weeks apart.
    • Dupuytren's continuation: The member must meet all initial criteria, continue treatment for the same cord, and have received fewer than 3 injections total per cord, 4 weeks apart. A new or recurrently treated cord must meet all initial criteria.
    • Peyronie's initial therapy: The disease must be stable without clinical changes for at least 3 months; the member must have a palpable plaque and curvature of 30 to 90 degrees, intact erectile function, and be at least 18 years old; treatment is limited to one course and no more than 8 injections total, including prior treatment.
    • Peyronie's continuation: The member must meet all initial criteria, have curvature of at least 15 degrees at the continuation request, and have received fewer than 8 injections total, including injections from previous treatment.
  3. The member will receive up to 3 injections maximum per cord as part of the current treatment, with injections 4 weeks apart.Maximum 3 injections per cord, 4 weeks apart
  4. Peyronie's Disease Initial Therapy

    Covered when all of the following are met:

    Peyronie's disease initial therapy

    • The member has stable Peyronie's disease without clinical changes, such as worsening curvature, for at least 3 months.Stable for ≥3 months
    • The member has a palpable plaque and curvature deformity of at least 30 degrees and no more than 90 degrees prior to initiating Xiaflex therapy.30–90 degrees
    • The member has intact erectile function, with or without medication.
    • The member is 18 years of age or older.≥18 years
    • The member will receive a maximum of one treatment course with a maximum of 8 injections total, including injections received for any previous treatment.One treatment course; maximum 8 total injections

    Peyronie's disease continuation

    • The member meets all initial authorization criteria.
    • The member has curvature deformity of at least 15 degrees at the time of the continuation request.≥15 degrees
    • The member has received fewer than 8 injections total, including injections received for any previous treatment.<8 total injections